GlassScriptPhysician profile
Allison S Remiker
NPI 1912264896
$12,098.30
in general payments reported to CMS, 2019-2025
7 companies · $98.77 in 2025
The $98.77 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,875 · 2023: $2,216 · 2024: $7,908 · 2025: $98.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,690 · Honoraria: $2,025 · Travel and Lodging: $1,483 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $610 · Food and Beverage: $332 · Education: $82.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,690.00 |
| Honoraria | $2,025.00 |
| Travel and Lodging | $1,483.13 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $610.00 |
| Food and Beverage | $332.18 |
| Education | $82.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| X4 Pharmaceuticals, INC. | $4,497.64 | 2024-2025 | Xolremdi |
| Pharming Healthcare, INC. | $2,093.13 | 2024 | Joenja |
| Horizon Therapeutics Plc | $2,025.00 | 2023 | Actimmune |
| Novartis Pharmaceuticals Corporation | $1,875.00 | 2022 | |
| Genetix Biotherapeutics INC | $1,220.00 | 2024 | |
| Sobi, INC | $262.56 | 2023-2025 | |
| Agios Pharmaceuticals, INC. | $124.97 | 2024 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Remiker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.